PHS
UTHR icon

PFM Health Sciences’s United Therapeutics UTHR Stock Holding History

PFM Health Sciences’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$27.2M Buy
+45,900
New +$22.9M 2.48% 10

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

PFM Health Sciences's UTHR Position: Q1 2026 in Review

PFM Health Sciences reduced its United Therapeutics (UTHR) stake by 41% in Q1 2026, selling an estimated $13.9M and leaving 39,805 shares worth $23.6M. The position accounts for 2.15% of the portfolio, ranked #11.

PFM Health Sciences first reported a position in UTHR in Q4 2024 and has held it in 5 quarters since. The position peaked at $40.1M in Q3 2025. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • PFM Health Sciences held 39,805 shares of United Therapeutics worth $23.6M as of Q1 2026.
  • PFM Health Sciences sold 27,938 United Therapeutics shares in Q1 2026, an estimated $13.9M.
  • United Therapeutics made up 2.15% of PFM Health Sciences's portfolio in Q1 2026, its #11 holding.
  • PFM Health Sciences first reported a position in United Therapeutics in Q4 2024 and has held it in 5 quarters since.
  • PFM Health Sciences's United Therapeutics position peaked at $40.1M in Q3 2025.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.